Table 4.
RNA based Vaccines and stages of development
| Developer / Researcher | Stage of Development | Product Description |
|---|---|---|
| Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences | Phase III | Adjuvanted recombinant protein (RBD-Dimer). (ZF2001) |
| Instituto Finlay de Vacunas | Phase III | rRBD produced in CHO-cell chemically conjugate to tetanus toxoid; (FINLAY-FR-2) (SOBERANA 02) |
| Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo | Phase III | Protein subunit; Full length recombinant SARs COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M; (NVX-CoV2373) (SARS-CoV-2 rS) |
| Medigen Vaccine Biologics Corp/ NIAID/ Dynavax | Phase II | MVC-COV1901 vaccine injection; S-2 P protein + CpG 1018 |
| Sanofi Pasteur/ GSK | Phase II | Protein subunit; S protein, baculovirus production |
| West China Hospital, Sichuan University | Phase II | RBD (baculovirus production expressed in Sf9 cells) |
| Biological E Ltd/ Dynavax/ Baylor College of Medicine | Phase I/II | Protein subunit; (BECOV2) |
| Center for Genetic Engineering and Biotechnology (CIGB), Havana | Phase I/II | CIGB-669 (RBD-AgnHB) |
| Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology “VECTOR” | Phase I/II | Peptide vaccine, EpiVacCorona |
| Instituto Finlay de Vacunas | Phase I/II | RBD + Adjuvant (FINLAY-FR-1) (SOBERANA 01) |
| Nanogen Pharmaceutical Biotechnology | Phase I/II | Recombinant SARS-CoV-2 spike protein, aluminum adjuvanted |
| Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan | Phase I/II | Recombinant protein vaccine S-268019, baculovirus expression |
| VIDO-InterVac, University of Saskatchewan | Phase I/II | Protein subunit, adjuvanted microsphere peptide, (COVAC-1 & COVAC-2) |
| Adimmune Corporation | Phase I | Baculovirus-insect cells expression system, spike (S) protein (tAdimrSC-2f) |
| Center for Genetic Engineering and Biotechnology (CIGB), Havana | Phase I | CIGB-66 (RBD + aluminum hydroxide) |
| Clover Biopharmaceuticals Inc./ Dynavax | Phase I | Protein subunit, native like trimeric subunit spike protein; (SCB-2019) |
| Covaxx/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia | Phase I | S1-RBD-protein; Multitope Peptide-Based Vaccine (MVP); UB-612 |
| Razi Vaccine and Serum Research Institute | Phase I | SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars) |
| University Hospital Tuebingen | Phase I | SARS-CoV-2 HLA-DR peptides, (CoVAC-1) |
| Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies | Phase I | Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19) |